Overview

• ARTEMIS-DELFI uses AI to analyze cfDNA fragmentation patterns, offering faster and more accurate therapeutic response monitoring for pancreatic cancer patients.
• Validated in two phase 2 trials, CheckPAC and PACTO, the test outperformed conventional imaging and tumor-informed assays like WGMAF.
• The test identifies treatment effectiveness as early as four weeks, enabling clinicians to adjust therapies swiftly through a 'fast-fail' approach.
• Unlike tumor-informed methods, ARTEMIS-DELFI operates independently of tumor biopsies, making it more accessible and applicable to diverse patient populations.
• Prospective studies are planned to assess its impact on patient survival and explore its use in monitoring other cancer types.